Neumora Therapeutics, Inc. (NMRA) stock
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.43−0.00 (-0.95%)
Close on Nov 13, 2026Market cap $80.59MP/E –Yield –
Neumora Therapeutics cash
Cash and short-term investments held at the end of each period.
Neumora Therapeutics's cash was $116.83M at Jun 30, 2026. For fiscal 2025 it was $182.53M, down 40.7% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.53M | -40.7% |
| FY2024 | Dec 31, 2024 | $307.58M | -32.2% |
| FY2023 | Dec 31, 2023 | $453.98M | +22.1% |
| FY2022 | Dec 31, 2022 | $371.88M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $116.83M | -46.3% |
| Q1 FY2026 | Mar 31, 2026 | $147.07M | -41.0% |
| Q4 FY2025 | Dec 31, 2025 | $182.53M | -40.7% |
| Q3 FY2025 | Sep 30, 2025 | $171.53M | -49.7% |
| Q2 FY2025 | Jun 30, 2025 | $217.59M | -41.5% |
| Q1 FY2025 | Mar 31, 2025 | $249.35M | -41.0% |
| Q4 FY2024 | Dec 31, 2024 | $307.58M | -32.2% |
| Q3 FY2024 | Sep 30, 2024 | $341.31M | -33.0% |
| Q2 FY2024 | Jun 30, 2024 | $371.64M | +82.0% |
| Q1 FY2024 | Mar 31, 2024 | $422.72M | +100.5% |
| Q4 FY2023 | Dec 31, 2023 | $453.98M | +22.1% |
| Q3 FY2023 | Sep 30, 2023 | $509.57M | +101.8% |
| Q2 FY2023 | Jun 30, 2023 | $204.22M | – |
| Q1 FY2023 | Mar 31, 2023 | $210.87M | – |
| Q4 FY2022 | Dec 31, 2022 | $371.88M | – |
| Q3 FY2022 | Sep 30, 2022 | $252.51M | – |
See a number that looks wrong?